Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bbmt.2020.04.008 http://scihub22266oqcxt.onion/10.1016/j.bbmt.2020.04.008 32298807!7194685!32298807     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biol+Blood+Marrow+Transplant 2020 ; 26 (7): 1239-1246 Nephropedia Template TP {{tp|p=32298807|t=2020. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic |pdf=|usr=}}{{32298807}} gab.com Text Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic JO: Biol Blood Marrow Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32298807 #FOAvip The SARS-CoV-2 coronavirus (COVID-19) pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. Based on the collective experience of the CAR T-cell Consortium investigators, we review and address several questions and concerns regarding cellular therapy administration in the setting of COVID-19 and make general recommendations to address these issues. Specifically, we address (1) necessary resources for safe administration of cell therapies; (2) determinants of cell therapy utilization; (3) selection among patients with B cell non-Hodgkin lymphomas and B cell acute lymphoblastic leukemia; (4) supportive measures during cell therapy administration; (5) use and prioritization of tocilizumab; and (6) collaborative care with referring physicians. These recommendations were carefully formulated with the understanding that resource allocation is of the utmost importance, and that the decision to proceed with CAR T cell therapy will require extensive discussion of potential risks and benefits. Although these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy. Twit Text FOAVip Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic ????Biol Blood Marrow Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32298807 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32298807 #FOAvip English Wikipedia <ref>{{Cite pmid|32298807}}</ref> Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic #MMPMID32298807 Bachanova V; Bishop MR; Dahi P; Dholaria B; Grupp SA; Hayes-Lattin B; Janakiram M; Maziarz RT; McGuirk JP; Nastoupil LJ; Oluwole OO; Perales MA; Porter DL; Riedell PA Biol Blood Marrow Transplant 2020[Jul]; 26 (7): 1239-1246 PMID32298807show ga The SARS-CoV-2 coronavirus (COVID-19) pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. Based on the collective experience of the CAR T-cell Consortium investigators, we review and address several questions and concerns regarding cellular therapy administration in the setting of COVID-19 and make general recommendations to address these issues. Specifically, we address (1) necessary resources for safe administration of cell therapies; (2) determinants of cell therapy utilization; (3) selection among patients with B cell non-Hodgkin lymphomas and B cell acute lymphoblastic leukemia; (4) supportive measures during cell therapy administration; (5) use and prioritization of tocilizumab; and (6) collaborative care with referring physicians. These recommendations were carefully formulated with the understanding that resource allocation is of the utmost importance, and that the decision to proceed with CAR T cell therapy will require extensive discussion of potential risks and benefits. Although these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy. |*Pandemics[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |COVID-19[MESH] |Communicable Disease Control[MESH] |Coronavirus Infections/*epidemiology/immunology[MESH] |Health Care Rationing/ethics/organization & administration[MESH] |Humans[MESH] |Immunotherapy, Adoptive/ethics/*methods[MESH] |Lymphoma, B-Cell/immunology/pathology/*therapy[MESH] |Pneumonia, Viral/*epidemiology/immunology[MESH] |Practice Guidelines as Topic[MESH] |Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/immunology/pathology/*therapy[MESH] |Receptors, Antigen, T-Cell/genetics/immunology[MESH] |Receptors, Chimeric Antigen/genetics/immunology[MESH] |T-Lymphocytes/cytology/immunology/*transplantation[MESH] |Tissue Donors/supply & distribution[MESH]Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic (epmc).pdf DeepDyve Pubget Overpricing